Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Fig. 2

Type of immune checkpoint inhibitor, treatment duration, dose intensity, and type and duration of response. For each patient, the bar length indicates the amount of time spent in a specific (color-coded) disease state. Abbreviations: AlloSCT allogeneic stem cell transplantation, MDS myelodysplastic syndrome, AML acute myeloid leukemia, CR complete response, ICI immune checkpoint inhibitor

Back to article page